Monte Rosa Therapeutics Inc (GLUE)
Monte Rosa Therapeutics Inc. is a clinical-stage biotechnology company focused on developing small molecule precision medicines designed to use the body’s natural protein-degradation pathways to target therapeutically relevant proteins. Its pipeline includes orally available molecular glue degraders such as MRT-2359 for MYC-driven tumors, MRT-6160 for neurologic and systemic autoimmune and inflammatory diseases, and MRT-8102 for inflammatory conditions associated with IL-1a, IL-1ß, IL-18, and damage-associated molecular patterns. The company is also advancing CDK2 for several cancer types, including ovarian, endometrial, gastric, and breast cancers. Beyond oncology, its research programs extend into immunology and inflammation, cardiovascular, metabolic, and genetic disease areas. Monte Rosa also develops QuEEN, a discovery engine supporting its target-centric MGD approach. The company has strategic collaboration and licensing agreements with F. Hoffmann-La Roche Ltd. and Novartis and is headquartered in Boston, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GLUE
|
$19.76
|
-17.6% Downside
|
Fair
|
$33.17
|
38.3% Upside
|
Undervalued
|
Good
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-15.6x
|
3.9x
|
47.2x
|
1.984 B
|
1.4 B
|
1.9%
|
63.9%
|
4.9
|
—
|
15.1%
|
